Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut by Parabilis, the largest IPO in the sector’s history. The analysts also discuss the Biosecure Act and U.S. policy toward China; the cachexia pipeline; and BioCentury’s updated Innovation Distillery. View full story: https://www.biocentury.com/article/659773 #BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech 00:36 - Innovation Distillery 03:56 - Biotech IPOs 10:13 - Biosecure Act, WuXi AppTec 16:03 - Cachexia Pipeline 22:03 - Ouster for RFK Jr.? To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

BioCentury This Week

# Full Transcript

**Podcast:** BioCentury This Week

## Participants

- **Jeff Cranmer** (BioCentury)
- **Simone Fishburn** (BioCentury)
- **Karen Tkach-Tusman** (BioCentury)
- **Stephen Hansen** (BioCentury)
- **Tierney Baum** (BioCentury)
- **Simone Fishburn** (BioCentury)
- **Steve Usdin** (BioCentury)

## Transcript

Biotech IPOs that do go out remain hot, but will that continue into the fall? Impact of the BioSecure Act is starting to come into focus and Wuxi Aptek is once again in the crosshairs of the U.S. government.

We'll discuss both on this week's BioCentury This Week podcast. We'll also take a look at how the political calendar will shape biopharma's future and what's in the clinic for cancer-associated cachexia.

But first, BioCentury is expanding its horizon scanning tools, data and analysis to help drug hunters track where translational science is heading next. Here to tell you about that is our Editor-in-Chief, Simone Fishburn, and our colleague, Karen Tkach-Tusman, Director of Biopharma Intelligence. So what's new, Simone? Karen?

Well, what's new is really just an expansion of what we've done. And so what we really lean into at BioCentury is horizon scanning. We now have, as you've been hearing, not one, but two Grand Rounds conferences each year, which is, you know, our horizon scanning, very forward-looking, what's the next science and solving scientific problems conferences.

So, one of the ways we've had are, we've been looking at this, but the distillery is a product we've had for a while. And we've now just expanded this in several dimensions and ways. So, one is there's just many more items, 200 plus a month that we're putting in there. The other is the scope of items. Now, what is the distillery?

Karen will explain a little more, but briefly, it is a tool that lets you find innovations from the academic literature that let you find items with translational potential that you might want to license or partner, or just know about the competitive intelligence. So, it's pretty exciting and it's a handy new interface that we've got. So, yeah, this is a really exciting time for the innovation distillery.

It's come a long way since the PDF-based products of 2008 when we launched it. Now, it is a database that's part of a module within BCIQ that is focused on the scientific papers coming out of the literature that highlight a really wide spectrum of innovations. Not just targets and compounds, but actually going beyond that to things like enabling tools and technology, both wet lab and computational,

to modality design and optimization approaches, things around say manufacturing or the little tweaks that make cell therapies better. And emerging disease biology that is not just when a paper has arrived at a neat conclusion around a specific target, but the disease atlases.

We've highlighted some of these in analyses where they kind of capture more, here's broad look at patient samples to understand the heterogeneity and mech...

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.